Chapter 12 Current management of hormone-refractory prostate cancer

[1]  D. Heitjan,et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A R Willan,et al.  Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Bubley,et al.  High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. , 1998, The Journal of urology.

[4]  O. Sartor,et al.  Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. , 1998, Urology.

[5]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[6]  S. Steinberg,et al.  Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  R. Rubens,et al.  A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. , 1997, European journal of cancer.

[8]  S. Litwin,et al.  Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Akakura,et al.  Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase. , 1997, Japanese journal of clinical oncology.

[10]  D. Smith,et al.  Megestrol acetate in the treatment of hormone refractory prostate cancer. , 1997, American journal of clinical oncology.

[11]  P. Schellhammer,et al.  Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. , 1997, The Journal of urology.

[12]  D. Stewart,et al.  Antiandrogen withdrawal syndrome with nilutamide. , 1997, Urology.

[13]  E. Small,et al.  Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. , 1997, The Journal of urology.

[14]  H. Klocker,et al.  Androgen Receptor Gene Mutations in Prostate Cancer , 1997, Drugs & aging.

[15]  R. Fine,et al.  Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. , 1996, Journal of the National Cancer Institute.

[16]  L. Chung,et al.  Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. , 1996, Journal of the National Cancer Institute.

[17]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Belldegrun,et al.  Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  O. Brawley,et al.  Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer. , 1996, Acta oncologica.

[20]  S. Steinberg,et al.  Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. , 1996, Cancer investigation.

[21]  M. Egorin,et al.  Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. , 1995, Journal of Clinical Oncology.

[22]  O. Sartor.  Prostate-specific antigen changes before and after administration of an angiogenesis inhibitor (tnp-470). , 1995, Oncology reports.

[23]  E. Small,et al.  The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer , 1995, Cancer.

[24]  D. Jodrell,et al.  Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Scher,et al.  Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. Scher,et al.  Hormone-refractory (D3) prostate cancer: refining the concept. , 1995, Urology.

[27]  M. R. Cooper,et al.  Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.

[28]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[29]  N. Bissada,et al.  Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol. , 1995, The Journal of urology.

[30]  N. Dawson,et al.  Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. , 1995, The Journal of urology.

[31]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[32]  B. Redman,et al.  Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Pienta,et al.  Oral etoposide in the treatment of hormone‐refractory prostate cancer , 1994, Cancer.

[34]  C. Vallejo,et al.  [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate]. , 1994, Actas urologicas espanolas.

[35]  C. Logothetis,et al.  Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Carroll,et al.  Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. , 1994, Urology.

[37]  S. Steinberg,et al.  Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. , 1994, Journal of the National Cancer Institute.

[38]  M. Tallman,et al.  A PHASE II STUDY OF CONTINUOUS INFUSION 5-FLUOROURACIL IN ADVANCED HOMRONEREFRACTORY PROSTATE CANCER : AN ILLINOIS CANCER CENTER STUDY. AUTHOR'S REPL Y , 1994 .

[39]  D. Grignon,et al.  High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. , 1994, In vivo.

[40]  L. Denis,et al.  Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–‐genitourinary group study 30853 , 1993, Cancer.

[41]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[42]  J. Grygiel,et al.  Oral cyclophosphamide for the management of hormone-refractory prostate cancer. , 1993, British journal of urology.

[43]  A. Benson,et al.  A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study , 1993, Cancer.

[44]  M. Koutsilieris,et al.  Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. , 1993, The Journal of urology.

[45]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Bauer,et al.  Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. , 1993, The Journal of urology.

[47]  D. Jodrell,et al.  Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I Trial , 1993 .

[48]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[49]  M Mazumdar,et al.  Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Yagoda,et al.  Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.

[51]  K. Tew,et al.  Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Steinberg,et al.  Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Fosså,et al.  Prognostic factors in hormone-resistant progressing cancer of the prostate. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  H. Scher,et al.  Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. , 1992, The Journal of urology.

[55]  A. McEwan,et al.  A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. , 1991, European journal of cancer.

[56]  T. Anderson,et al.  Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. , 1991, Urology.

[57]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[58]  D. Gillatt,et al.  High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response. , 1989, Urology.

[59]  P. Goodman,et al.  A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. , 1989, The New England journal of medicine.

[60]  I. Tannock,et al.  Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  E. Gelmann,et al.  EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO , 1985, The Lancet.

[62]  D. Citrin,et al.  A phase II study of high‐dose estrogens (diethylstilbestrol diphosphate) in prostate cancer , 1985, Cancer.

[63]  M. Soloway,et al.  Estramustine phosphate--hormone, chemotherapeutic agent, or both? , 1984, Urology.

[64]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[65]  H. Yde.  EXPLORATION OF INDEPENDENCE. , 1964, The Lancet.